Atlanta, GA., May 15, 2013 – Galectin Therapeutics (NASDAQ: GALT) will host a conference call

at 9:30 A.M. Eastern Time on Thursday, May 23, 2013, to provide an update following the

Company’s Annual Meeting of Shareholders. Additionally, Peter Traber, MD, President, CEO and

CMO of Galectin Therapeutics, will update the investment community on the Company’s

pipeline of galectin inhibitor compounds and progress in its development of treatments for liver

fibrosis and cancer.

Following his presentation, Dr. Traber will answer questions from shareholders present at the

meeting. Shareholders not attending the meeting may submit questions in advance for Dr.

Traber’s consideration; questions should be submitted via email to

IR@galectintherapeutics.com no later than May 21, 2013.

The conference call and presentation will be webcast live over the internet and can be accessed

by logging on to the Galectin Therapeutics website at www.galectintherapeutics.com.

The audio portion of the call can also be accessed by dialing (888) 327-8914 (toll-free

within the United States) or (847) 944-7654 (toll, from outside the United States). The

passcode for participants is 7827311#

Please log in approximately 10 minutes before the event to ensure a timely connection.

The webcast will also be archived on the Company’s website.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for

fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key

mediators of biologic function. We are leveraging extensive scientific and development expertise as well

as established relationships with external sources to achieve cost effective and efficient development.

We are pursuing a clear development pathway to clinical enhancement and commercialization for our

lead compounds in liver fibrosis and cancer. Additional information is available at

http://www.galectintherapeutics.com.

Contact

Galectin Therapeutics Inc.
Dr. Harold H. Shlevin (678)-615-3213
Chief Operating Officer
shlevin@galectintherapeutics.com

Norcross, GA (May 10, 2013) – Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of

therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results

for the first quarter, ended March 31, 2013. These results are included in the Company’s Quarterly

Report on Form 10-Q, which has been filed with the SEC.

“During the first quarter of 2013 we completed a significant milestone with the submission of an IND for

GR-MD-02 and the FDA’s ok that we could proceed with a Phase 1 clinical trial,” said Peter G. Traber,

M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. “We engaged

CTI Clinical Trial Services to provide services related to a Phase 1 clinical trial of GR-MD-02 in patients

with nonalcoholic steatohepatitis (NASH) and liver fibrosis and expect to begin enrolling patients in this

trial in the second quarter of 2013, with expected top line results sometime late in 2013 or early 2014.

The novel mechanism of action of GR-MD-02, in combination with compelling preclinical data, gives us

great hope that this compound may ultimately meet the needs of patients with this deadly disease that

currently has no approved therapeutic options.”

At March 31, 2013, the Company had $7.0 million of non-restricted cash and cash equivalents available

to fund future operations and the Company believes is sufficient cash to fund core operations and

planned research and development through the first quarter of 2014.

For the first quarter of 2013, the Company reported a net loss applicable to common stock of $3.5

million, or ($0.22) per share, basic and diluted, compared with a net loss of $2.2 million or ($0.17) per

share for the same period in 2012. The weighted average number of shares used to calculate loss per

share increased for the 2013 period compared to the 2012 period due primarily to the March 2012

offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the first quarter of 2013 was $1.8 million, compared with $0.9

million for the same period in 2012. The increase is due primarily to clinical program expenses related to the

Phase I clinical trial agreement we entered into with CTI during the three months ended March 31, 2013. As we

begin enrolling patients in the Phase I trial we expect our clinical activities costs may increase and will fluctuate

from quarter to quarter as the trial progresses.

General and administrative expense for the first quarter of 2013 was $1.5 million, compared with $1.1

million for the same period in 2012. The primary reasons for the increase is due to increased stock-based

compensation, legal expenses and public company related costs, offset by decreased facilities costs as we moved

the location of our headquarters to Georgia.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the

treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin

proteins, key mediators of biologic function. We are leveraging extensive scientific and development

expertise as well as established relationships with external sources to achieve cost effective and efficient

development. We are pursuing a clear development pathway to clinical enhancement and

commercialization for our lead compounds in liver fibrosis and cancer. Additional information is

available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future

events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and

others. They are based on our current expectations and are subject to factors and uncertainties which

could cause actual results to differ materially from those described in the statements. Factors that could

cause our actual performance to differ materially from those discussed in the forward-looking

statements include, among others: incurrence of operating losses since our inception, uncertainty as to

adequate financing of our operations, extensive and costly regulatory oversight that could restrict or

prevent product commercialization, inability to achieve commercial product acceptance, inability to

protect our intellectual property, dependence on strategic partnerships, product competition, and

others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all

risks or that others may emerge which we do not anticipate. You should not place undue reliance on

forward-looking statements. Although subsequent events may cause our views to change, we disclaim

any obligation to update forward-looking statements.

Contact:
Tom McGauley
Chief Financial Officer
678-620-3186
ir@galectintherapeutics.com

Norcross, GA, April 29, 2013 – Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today released data that was presented on April 27, 2013 at the International Liver Congress in Amsterdam, The Netherlands. The data were generated by the laboratory of Dr. Scott Friedman of the Icahn School of Medicine at Mount Sinai, a world renowned investigator and expert on liver fibrosis. GR-MD-02 and GM-CT-01, drugs that inhibit galectin proteins, were found to reverse the most advanced stage of liver fibrosis, called cirrhosis, in experimental animals given toxin-induced cirrhosis.

“The findings of these experiments show that the anti-galectin drugs had a robust effect on cirrhosis, including reversal of tissue architectural changes in the liver that result from fibrosis as well as reduction in portal hypertension, an important pathophysiological effect of cirrhosis,” said Dr. Friedman, Dean for Therapeutic Discovery and Chief, Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. “The experimental design of these studies provided a very high hurdle for any drug to show effectiveness, and yet both GR-MD-02 and GM-CT-01 passed the test. These drugs are excellent candidates for evaluation in human cirrhosis.”

“We are gratified that one of the most prominent investigators in the world has shown that our galectin inhibitors were effective in experimental cirrhosis, the most severe form of liver fibrosis, for which there are no currently approved medical therapies” said Dr. Peter G. Traber, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics. “Along with the multiple studies we have presented on liver fibrosis from fatty liver disease, these findings provide added confidence for the potential of this approach in studies of human liver fibrosis and cirrhosis.”

The data presented at the International Liver Congress which is sponsored by the European Association for the Study of the Liver (EASL) are posted on the Company website at http://bit.ly/14xDpKK. Rats were treated with a liver toxin which produced fibrosis that replaced over 25% of the liver tissue and resulted in architectural changes consistent with cirrhosis. While continuing to treat with the liver toxin, rats were treated with either a placebo or four weekly injections of either GR-MD-02 or GM-CT-01. The livers were reviewed by a highly qualified liver pathologist who was unaware of the treatments that the animals had received. Both drugs significantly reduced the amount of fibrotic tissue, and most importantly, reversed the histological findings of cirrhosis. Additionally there was a reduction in the blood pressure in the blood system supplying the liver (portal pressure) in the treated animals. Cirrhosis and portal hypertension are the primary abnormalities that lead to complications and death in humans with liver fibrosis. Galectin previously announced initiation of a Phase 1 clinical trial of GR-MD-02 in patients with fatty liver disease (NASH, non-alcoholic steatohepatitis) with advanced fibrosis which is expected to begin enrolling patients in May 2013 (http://bit.ly/11wj6hr).

About Galectin Therapeutics Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact

Galectin Therapeutics, Inc.
Peter G. Traber
Chief Executive Officer
(678) 620-3186
ir@galectintherapeutics.com

NORCROSS, Ga., April 17, 2013  – Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that its abstract was accepted by the European Association for the Study of the Liver for presentation on April 27, 2013 at the International Liver Congress to be held in Amsterdam, The Netherlands. The abstract, “Regression of fibrosis and reversal of cirrhosis in thioacetamide-induced liver fibrosis following treatment with galectin inhibitors” provides evidence in a pre-clinical model that Galectin’s drugs are able to reverse established fibrosis and cirrhosis.

“Data continues to accumulate showing the effectiveness of our galectin inhibitor drugs in pre-clinical models,” said Dr. Peter G. Traber, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics. “Research will be presented on how both GR-MD-02 and GM-CT-01 are effective in reversing fibrosis and cirrhosis in established disease. The findings add confidence for the possibility of this mechanism extending to human disease. Following the presentation, additional information will be announced and the data will be posted on the Galectin website.”

About Galectin Therapeutics


Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact

Galectin Therapeutics Inc.
Peter G. Traber
Chief Executive Officer
(678) 620-3186
ir@galectintherapeutics.com

FOR IMMEDIATE RELEASE 

Clinical Trial Sites for First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis Announced by Galectin Therapeutics 

Norcross, GA, April 9, 2013 – Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis. The Phase 1 Clinical Trial is entitled, “A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects with Non-Alcoholic Steatohepatitis (NASH) with Advanced Hepatic Fibrosis” and will be conducted in six centers in the United States which have extensive experience in conducting clinical trials in liver disease.

“We are delighted to have recruited world class US investigators in NASH to conduct this initial study in our development program to treat liver fibrosis associated with fatty liver,” said Dr. Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. “The clinical trial will be conducted in patients with NASH and advanced fibrosis who will receive four weekly doses of GR-MD-02 and, while evaluation for safety is the primary objective, a series of biomarkers will be evaluated to assess for early signs of efficacy. Therefore, we anticipate obtaining more data from this study than the typical Phase 1 clinical trial.”

The clinical trial investigator kick-off meeting was held in Atlanta GA on April 5 2013, led by Galectin and CTI Clinical Trials & Consulting Services Inc of Cincinnati Ohio, a full service clinical research organization with extensive experience in liver-related clinical trials. The investigators and sites that will conduct the study include: Dr. Stephen Harrison of the Brooke Army Medical Center at Fort Sam Houston in San Antonio TX, Dr. Naga Chalasani of Indiana University School of Medicine in Indianapolis IN, Dr. Brent Tetri of St. Louis University School of Medicine in St. Louis MO, Dr. Arun Sanyal of Virginia Commonwealth University School of Medicine in Richmond VA, Dr. Ram Subramanian of Emory University School of Medicine in Atlanta GA, and Dr. Thomas Schiano of Icahn School of Medicine at Mount Sinai in New York City. It is anticipated that the enrollment and infusion of the first cohort will be completed by the end of Q2 2013.

The study is planned to enroll the first cohort followed by potential sequential cohorts receiving increasing doses of GR-MD-02 with eight patients in each cohort randomized 6:2 (study drug:placebo); the patients and medical staff will be blinded to whether the patient is receiving drug or placebo. After the safety of the first dose is assessed, the patients will receive three additional doses weekly doses of GR-MD-02. The dose will be increased after assessment of each cohort to presumptive target therapeutic levels which is currently projected to take one year from the start of the study. In addition to patient safety and GR-MD-02 pharmacokinetics, each patient will have assessment of over two dozen biomarkers of NASH and fibrosis to evaluate for an early indication of drug effect.

About NASH 

NASH has become a common disease of the liver with the rise in obesity rates, affecting 9 to 15 million people, including children, in the United States. NASH is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with NASH can develop fibrosis, or scarring of the liver, and it is estimated that as many as 3,000,000 will develop cirrhosis, a severe liver disease where transplantation is the only current treatment available. Approximately 6,300 liver transplants are done on an annual basis in the United States. There are currently not approved medical therapies for NASH or fibrosis of the liver.

About Galectin Therapeutics Inc. 

Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements 

This press release contains, in addition to historical information, statements that look forward in time or that express management’s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include our plans, expectations and goals regarding the clinical trial and estimates regarding those impacted by NASH. Our plans, expectations and goals regarding the clinical trial are subject to factors beyond our control. Our clinical trial may not begin or produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including GR-MD-02, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact 

Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO & CMO
ir@galectintherapeutics.com

FOR IMMEDIATE RELEASE

Galectin Therapeutics Inc. Receives OK from FDA to Proceed with First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis

NORCROSS, GA, March 5, 2013 – Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that following review of its Investigational New Drug (IND) application, the US Food and Drug Administration (FDA) notified the company that it may proceed with a Phase 1 clinical trial. The first-in-man Phase 1 clinical trial will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis.

“There are currently no approved medical treatments available for patients with NASH and advanced fibrosis. This decision by the FDA is an important milestone in our clinical development program to bring forward a treatment option for these patients,” said Dr. Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. “We have recruited a world-class group of clinical investigators and engaged CTI of Cincinnati Ohio, a full service Clinical Research Organization with extensive experience in liver-related clinical trials, to run the operations of the Phase 1 clinical trial.”

The Phase 1 Clinical Trial is entitled, “A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects with Non-Alcoholic Steatohepatitis (NASH) with Advanced Hepatic Fibrosis” and will be conducted in up to seven centers in the United States. It is anticipated that the enrollment and infusion of the first cohort will begin in May, 2013. Future communications will outline study sites and investigators, notification of first infusion of patients, and expected milestone timings for the study.

About NASH

NASH has become a common disease of the liver with the rise in obesity rates, affecting 9 to 15 million people, including children, in the United States. NASH is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with NASH can develop fibrosis, or scarring of the liver, and it is estimated that as many as 3,000,000 will develop cirrhosis, a severe liver disease where transplantation is the only current treatment available. Approximately 6,300 liver transplants are done on an annual basis in the United States.

About Galectin Therapeutics Inc.

Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains, in addition to historical information, statements that look forward in time or that express management’s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include our plans, expectations and goals regarding the clinical trial and estimates regarding those impacted by NASH. Our plans, expectations and goals regarding the clinical trial are subject to factors beyond our control. Our clinical trial may not begin or produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including GR-MD-02, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31, 2011, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact

Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO & CMO
ir@galectintherapeutics.com

Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with the University of Georgia

Norcross, GA, February 19, 2013 – Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today the establishment of a collaborative drug discovery program with Dr. Geert-Jan Boons’ laboratory located in the Complex Carbohydrate Research Center at the University of Georgia. This program is focused on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role, including cancer and inflammatory and fibrotic disorders.

“Galectins play a critical role in many diseases and developing a pipeline of drugs that can target galectins is an important goal as follow-on compounds for our drugs currently in development and to extend the potential indications and routes of administration,” said Peter G. Traber, MD, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics. “We are extremely excited about our collaboration with the world-class Complex Carbohydrate Research Center and Dr. Boons, who is a world renowned and preeminent carbohydrate chemist. There is no better place in the world to conduct these investigations than the University of Georgia.”

“Galectin Therapeutics’ expertise in galectin science and drug discovery and the ability of my laboratory to prepare panels of complex carbohydrates provides an ideal combination of scientific expertise to develop the next generation of therapeutics for fibrosis and cancer,” said Dr. Geert-Jan Boons of the Complex Carbohydrate Research Center.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

About Complex Carbohydrate Research Center, University of Georgia

The Complex Carbohydrate Research Center was founded at the University of Georgia in 1985, and is one of only three centers worldwide dedicated to the study of complex carbohydrates, which play critical roles in cellular communication, gene expression, immunology, organism defense mechanisms, growth and development. The 140,000-square-foot facility is home to 17 interdisciplinary research groups, including four federally designated centers for carbohydrate research. In addition to UGA research projects, the center also provides analytical services and training to university, government and industrial scientists interested in complex carbohydrate molecules. For more information, see www.ccrc.uga.edu.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to factors and uncertainties which
could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact

Galectin Therapeutics Inc.
Peter G. Traber,MD
President,CEO,& CMO
678-620-3186
ir@galectintherapeutics.com

University of Georgia
James Hataway
Research Communications
706-542/5222
jhataway@uga.edu

“Dave Gentry interviews Jim Czirr, executive chairman of Galectin Therapeutics (NasdaqCM: GALT). Galectin Therapeutics is a promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function.

“The RedChip Money Report”™ delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The show is hosted by Dave Gentry, a leading authority on small-cap stocks and president of RedChip, an international small-cap research firm and an Inc. 5000 company. Mr. Gentry has made multiple guest appearances on both CNBC and Fox Business News and has been a consultant to hundreds of public companies.

“The RedChip Money Report”™ airs Saturdays at 2:30 p.m. on Fox Business News, a premium business network reaching more than 65 million homes nationwide. The weekly program also airs on My Family TV and TUFF TV.”

Galectin Submits IND For GR-MD-02

• On The Cusp Of Entering Clinical Development.

Yesterday, Galectin announced that it had successfully submitted the Investigational New Drug (IND) application with the FDA for permission to begin first-in-man testing of its lead drug candidate GR-MD-02, in line with previous guidance indicating that the submission would be completed by the end of January 2013. A Phase 1 study of the drug could begin before the end of 1Q 2013 and is expected to yield data later in the year. The firm’s Phase 2 study in non-alcoholic steatohepatitis (NASH), a highly unmet medical need with no currently-approved effective therapy, could begin before the end of 2013 and yield data in early 2015, potentially paving the way for a transformative partnership or potentially an acquisition of the company. We aim to draw investors’ attention to Galectin’s current valuation, which represents an attractive entry point, in our view. In anticipation of additional value-driving catalysts from both the GR-MD-02 program in liver fibrosis and the ongoing GM-CT-01 program in cancer, we reiterate our Buy rating and price target of $7.00 per share, which we currently anticipate being attained within the next 12 months. In our view, the firm is an undiscovered gem that possesses a technology platform founded upon cutting-edge science and validated targets.

• Attractive Comparable Metrics.

In recent months, the progress of a firm that has certain attributes in common with Galectin Therapeutics has demonstrated the appetite of investors for drug development opportunities in hepatology. The firm in question, Intercept Pharmaceuticals, went public in October 2012 at a valuation of $235mm and already has an enterprise value of roughly $650mm. Galectin, meanwhile, trades at an enterprise value of about $40mm. Intercept has yet to begin Phase 3 testing of its lead drug candidate, obeticholic acid (OCA or INT-747) in NASH. We also believe that OCA is unlikely to reverse fibrosis and that its safety profile may prove inferior to that of Galectin’s GR-MD-02. Given the high unmet need in liver fibrosis, we believe peak global sales for a drug that can reverse fibrosis could be $1.7 billion in 2020. In our opinion, there is very strong preclinical proof that Galectin’s drugs can reverse liver fibrosis.

• Strong Data From Second Lead Drug.

From Phase 1 and 2 studies with the firm’s lead drug candidate GM-CT-01, there is solid safety and encouraging signs of efficacy in colorectal cancer. Additional efficacy data could come on an ongoing basis from a study currently running in Germany that is assessing the impact of GM-CT-01 in skin cancer.


Please click here for full report

Galectin Therapeutics Inc. Announces Submission of an Investigational New Drug (IND) Application for the Treatment of Fatty Liver Disease

Norcross, GA, January 31, 2013 – Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013. The IND application supports a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis, or fatty liver disease.

“This IND submission is the first step in the clinical development program of GR-MD-02 for the treatment of liver fibrosis,” said Dr. Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. “We are leveraging our leadership in galectin science to bring new treatment options for these severely underserved patients and strongly believe that our novel approach of inhibiting galectin may be the key to the prevention and reversal of liver fibrosis.”

The IND application includes twenty seven (27) individual studies that characterize the pharmacology, pharmacokinetics, and toxicology of GR-MD-02 in a number of animal species, including the effects in various animal models of disease. Additionally, the application describes the manufacture of the drug substance and drug product to be used in human clinical trials. This information provides a description of how the drug works and why we believe it is likely to be safe in humans and provides a description of its possible mechanism of action in humans. The main purpose of the IND is to share with the FDA the extensive non-clinical data that we believe predicts for an acceptable safety profile when GR-MD-02 is first administered to humans in the initial early-stage clinical studies. The FDA will review this application and determine the acceptability of the data to predict the safety of GR-MD-02 before Galectin Therapeutics begins an initial human Phase 1 clinical trial. It is possible that the FDA will require additional information. If the FDA determines that the submitted package of data is acceptable, the Company plans on proceeding with a Phase 1 clinical trial. Future communications will outline study design and timing.

About NASH

NASH has become a common disease of the liver with the rise in obesity rates, affecting 9 to 15 million people, including children, in the United States. NASH is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with NASH can develop fibrosis, or scarring of the liver, and it is estimated that as many as 3,000,000 will develop cirrhosis, a severe liver disease where transplantation is the only current treatment available. Approximately 6,300 liver transplants are done on an annual basis in the United States.

About Galectin Therapeutics Inc.

Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains, in addition to historical information, statements that look forward in time or that express management’s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include our goals regarding the IND application, our plans for a clinical trial and estimates regarding those impacted by NASH. Our goals regarding the proposed indication of GR-MD-02 and related trials and approval are subject to factors beyond our control. Our IND application may not be approved in a timely fashion, if at all, and the FDA may require changes to our application that could prove time consuming and costly. To the degree we are able to conduct clinical trials, we may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including GR-MD-02, are subject to change at any time based on the changing needs of our company as determined by management. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31, 2011, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact

Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO & CMO
ir@galectintherapeutics.com